Quantitative Assessment of PALB2 and BRIP1 Genes Expression in the Breast Cancer Cell Line under the Influence of Tamoxifen
PALB2 and BRIP1 Genes Expression under Tamoxifen
DOI:
https://doi.org/10.31661/gmj.v12i.2483Abstract
Background:Breast cancer is considered one of the leading causes of mortality in the world. Cancer incidence and consequently, drug consumption can strongly influence gene expressions at the transcriptome level. Therefore, the assessment of the candidate biomarkers’ gene expression can accelerate the diagnosis process and increase the chance of treatment and remission. In this regard, the quantitative assessment of Partner and localizer of BRCA2 (PALB2) and BRCA1 Interacting Helicase 1 (BRIP1) genes expression in the breast cancer cell line under the treatment of Tamoxifen (TAM) was executed in this study. Materials and Methods :MCF7 cells were cultured as TAM-treated and control groups. RNA extraction and cDNA synthesis were performed based on the instructions of provided kits. qPCR Hi-ROX Master Mix kit was applied to the Quantitative Real-Time Polymerase Chain Reaction (Q-PCR). The outputs of Q-PCR were analyzed by REST statistical software. Results:Outcomes derived from data analysis of BRIP1 gene expression did not show any significant difference between the gene expression of control and TAM-treated groups. The expression of PALB2 was significantly higher in the TAM-treated group compared to the control group (P<0.05). Conclusion:Our findings showed a significant alteration between PALB2 gene expression in the TAM-treated breast cancer cell line and the control cell line. The quantitative assessment of mentioned genes as possible markers could be considered a non-invasive method for breast cancer in the processes of prognostic evaluations, screening, and treatment monitoring.
References
Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7): e48-e72
https://doi.org/10.5858/134.7.e48
PMid:20586616
Mohammadpour A, Jahangirian E, Moharrami T, Goljah Rad G, Javanparast Sheikhani L, Taghizadeh S. Breast Cancer, Genetic Factors and Methods of Diagnosis. Sarem J Reprod Med. 2020;4(4):198-207.
https://doi.org/10.52547/sjrm.4.4.198
Barzaman K, Karami J, Zarei Z, Hosseinzadeh A, Kazemi MH, Moradi-Kalbolandi S, et al. Breast cancer: Biology, biomarkers, and treatments. Int Immunopharmacol. 2020.
https://doi.org/10.1016/j.intimp.2020.106535
PMid:32361569
Klinge C. Non-Coding RNAs in Breast Cancer: Intracellular and Intercellular Communication. Non-Coding RNA. 2018;4(4):40.
https://doi.org/10.3390/ncrna4040040
PMid:30545127 PMCid:PMC6316884
Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clinic Oncol. 2014;32(21):2255.
https://doi.org/10.1200/JCO.2013.54.2258
PMid:24868023 PMCid:PMC4876310
Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2(3):205.
https://doi.org/10.1038/nrd1031
PMid:12612646
Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer. 2004;11(4):643-58.
https://doi.org/10.1677/erc.1.00776
PMid:15613444
Piggott L, da Silva AM, Robinson T, Santiago-Gómez A, Simões BM, Becker M, et al. Acquired resistance of ER-positive breast cancer to endocrine treatment confers an adaptive sensitivity to TRAIL through post-translational downregulation of c-FLIP. Clin Cancer Res. 2018: 1381.2017.
https://doi.org/10.1158/1078-0432.CCR-17-1381
PMid:29363524
Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer I. 2004;96(12):926-35.
https://doi.org/10.1093/jnci/djh166
PMid:15199112
Li X, Rouchka EC, Brock GN, Yan J, O'Toole TE, Tieri DA, et al. A combined approach with gene-wise normalization improves the analysis of RNA-seq data in human breast cancer subtypes. PloS one. 2018;13(8): e0201813.
https://doi.org/10.1371/journal.pone.0201813
PMid:30089167 PMCid:PMC6082555
Kwei KA, Kung Y, Salari K, Holcomb IN, Pollack JR. Genomic instability in breast cancer: pathogenesis and clinical implications. Mol Oncol. 2010;4(3):255-66.
https://doi.org/10.1016/j.molonc.2010.04.001
PMid:20434415 PMCid:PMC2904860
Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkäs K, Roberts J, Lee A, Subramanian D, De Leeneer K, Fostira F, Tomiak E. Breast-cancer risk in families with mutations in PALB2. New Engl J Med. 2014;371(6):497-506.
https://doi.org/10.1056/NEJMoa1400382
PMid:25099575 PMCid:PMC4157599
Amirhamzeh SA, Esfahani K, Salahshourifar I, Moslemi E. Evaluation of PALB2 Gene Expression in Breast Cancer. Journal of Sciences, Islamic Republic of Iran. 2020.
Shafiee E, Hesampour A. Quantitative study of PALB2 and BRIP1 gene expression in the population of Iranian women with Breast cancer compared to controls. Medic Sci J Islamic Azad Uni. 2019. 28(4):283-289.
https://doi.org/10.29252/iau.28.4.283
Kharrati-Koopaee H, Ebrahimie E, Dadpasand M, Niazi A, Esmailizadeh A. Genomic analysis reveals variant association with high altitude adaptation in native chickens. Sci Rep. 2019 Jun 25;9(1):9224
https://doi.org/10.1038/s41598-019-45661-7
PMid:31239472 PMCid:PMC6592930
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25(4):402-8.
https://doi.org/10.1006/meth.2001.1262
PMid:11846609
Li N, Zethoven M, McInerny S, et alContribution of large genomic rearrangements in PALB2 to familial breast cancer: implications for genetic testingJournal of Medical Genetics Published Online First: .2022.
https://doi.org/10.1136/jmedgenet-2021-108399
PMid:35396271
Dorling L, Carvalho S, Allen J, González-Neira A. et al. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. N Engl J Med. 2021. 4;384(5):428-439.
Wu S, Zhou J, Zhang K, Chen H, Luo M, Lu Y, Sun Y, Chen Y. Molecular mechanisms of PALB2 function and its role in breast cancer management. Fron Oncol. 2020. 28;10:301.
https://doi.org/10.3389/fonc.2020.00301
PMid:32185139 PMCid:PMC7059202
Mistry DA, French PW. Circulating Phospholipids as Biomarkers of Breast Cancer: A Review. Breast Cancer (Auckl). 2016; 10:191-196.
https://doi.org/10.4137/BCBCR.S40693
PMid:27867299 PMCid:PMC5110222
Thompson ER, Rowley SM, Li N, McInerny S, Devereux L, Wong-Brown MW, et al. Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care. J Clin Oncol. 2016; 34:1455-59.
https://doi.org/10.1200/JCO.2015.63.7454
PMid:26786923
Huber-Keener KJ, Liu X, Wang Z, Wang Y, Freeman W, Wu S, Planas-Silva MD, Ren X, Cheng Y, Zhang Y, Vrana K, Liu CG, Yang JM, Wu R. Differential gene expression in tamoxifen-resistant breast cancer cells revealed by a new analytical model of RNA-Seq data. PLoS One. 2012;7(7):e41333.
https://doi.org/10.1371/journal.pone.0041333
PMid:22844461 PMCid:PMC3402532
Men X, Ma J, Wu T, Pu J, Wen S, Shen J, Wang X, Wang Y, Chen C, Dai P. Transcriptome profiling identified differentially expressed genes and pathways associated with tamoxifen resistance in human breast cancer. Oncotarget. 2017. 26;9(3):4074-4089.
https://doi.org/10.18632/oncotarget.23694
PMid:29423105 PMCid:PMC5790522
Xu E, Guan T, Hu M, Tong D, Ge R, Liu Y. Establishment and transcriptome characterization of tamoxifen-resistant canine mammary gland tumor cells. Research in Veterinary Science. 2022. 1;145:135-46.
https://doi.org/10.1016/j.rvsc.2022.02.018
PMid:35193047
. Li Z, Yu D, Li H, Lv Y, Li S. Long noncoding RNA UCA1 confers tamoxifen resistance in breast cancer endocrinotherapy through regulation of the EZH2/p21 axis and the PI3K/AKT signaling pathway. International journal of oncology. 2019. 1;54(3):1033-42.
https://doi.org/10.3892/ijo.2019.4679
Gupta I, Ouhtit A, Al-Ajmi A, Rizvi SG, Al-Riyami H, Al-Riyami M, Tamimi Y. BRIP1 overexpression is correlated with clinical features and survival outcome of luminal breast cancer subtypes. Endocrine connections. 2018. 1;7(1):65-77.
https://doi.org/10.1530/EC-17-0173
PMid:29138235 PMCid:PMC5744628
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Galen Medical Journal
This work is licensed under a Creative Commons Attribution 4.0 International License.